MTOR and neoplasm: Indeed, combinatorial application of SCD1 small molecule inhibitor, A939572, with mTOR inhibitor, Temsirolimus, synergistically attenuated in vitro and in vivo tumor growth in advanced/metastatic ccRCC patients [253].